CanWell announced today that Dr. Bernard A. Fox is appointed as the Advisor of CanWell’s Scientific Advisory Committee (SAC). Dr. Fox is a leading researcher in the field of cancer immunotherapy and currently serves as the Chief and Director of the Molecular and Tumor Immunology Laboratory at the Earle A. Chiles Research Institute and the Providence Cancer Center. He is also an Associate Professor in the Department of Molecular and Immunology at the Oregon Health and Science University and a member of the Tumor Immunology Group at the OHSU Knight Cancer Institute. Dr. Fox is the founder and CEO of UbiVac, a clinical-stage immunotherapy biotech company.
Dr. Fox is currently the President of the World Immunotherapy Council (WIC), an association composed of a large number of international cancer immunotherapy organizations in 22 countries. He has also served as the former President of the Society for Immunotherapy of Cancer (SITC) and a member of the National Cancer Institute (NCI), National Institutes of Health (NIH), and Cell, Tissue and Gene Therapy Advisory Committee (CBER) at the US Food and Drug Administration (FDA). Dr. Fox has more than 30 years of experience in cancer immunotherapy and is recognized as a pioneer in this field. He has served as a scientific advisor to numerous well-known pharmaceutical companies, including AstraZeneca, BMS, Cell Genesys, Dendreon, Merck Serono, J&J, Mannkind, Micromet, Novartis, PerkinElmer, and Pfizer.